Contract research organisation Open Orphan plc (AIM:ORPH) (Euronext Growth:ORPH) announced on Tuesday a GBP7.2m deal for its subsidiary hVIVO.
This contract with an unnamed top 5 global pharmaceutical company is for testing of its orally administered antiviral product using hVIVO's respiratory syncytial virus (RSV) human challenge study model.
Commencing in June 2022, the Phase 2a double-blinded placebo-controlled human challenge study will evaluate the safety and efficacy profile of the antiviral against RSV.
The client's antiviral is currently in Phase III clinical trials for another infectious disease indication.
(USD1=GBP0.82)
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial